Fieke Hoeijmakers

Fieke Hoeijmakers

Auto-generated profile, based on publicly available information

Fieke Hoeijmakers

Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
FHFieke Hoeijmakers
Fieke Hoeijmakers
KHKoen J Hartemink
Koen J Hartemink
AVAd F Verhagen
Ad F Verhagen
WSWillem H. Steup
Willem H. Steup
EMElske Marra
Elske Marra
MWMichel Wouters
Michel Wouters
: OBJECTIVES: Persistent air leak (PAL; >5 days after surgery) is the most common complication after pulmonary resection and associated with prolonged hospital stay and increased morbidity. Literature is contradictory about the prevention and treatment of PAL. Variation is therefore hypothesized. The aim of this study is to understand the variation in the incidence, preventive management and treatment of PAL. METHODS: Data from the Dutch Lung Cancer Audit for Surgery were combined with results of an online survey among Dutch thoracic surgeons. The national incidence of PAL and case-mix corrected between-hospital variation were calculated in patients who underwent an oncological (bi)lobectomy or segmentectomy between January 2012 and December 2018. By multivariable logistic regression, factors associated with PAL were assessed. A survey was designed to assess variation in (preventive) management and analysed using descriptive statistics. Hospital-level associations between management strategies and PAL were assessed by univariable linear regression. RESULTS: Of 12 382 included patients, 9.0% had PAL, with a between-hospital range of 2.6–19.3%. Factors associated with PAL were male sex, poor lung function, low body mass index, high American Society of Anesthesiologists (ASA) score, pulmonary comorbidity, upper lobe resection, (bi)lobectomy (vs segmentectomy), right-sided tumour and robotic-assisted thoracic surgery. Perioperative (preventive) management of PAL differed widely between hospitals. When using water seal compared to suction drainage, the average incidence of PAL decreased 2.9%. CONCLUSIONS: In the Netherlands, incidence and perioperative (preventive) management of PAL vary widely. Using water seal instead of suction drainage and increasing awareness are potential measures to reduce this variation.

1 December 2020 in Chest
Verified
Journal Article
Open access
FHFieke Hoeijmakers
Fieke Hoeijmakers
DHDavid J. Heineman
David J. Heineman
JDJohannes M. Daniels
Johannes M. Daniels
NBNaomi Beck
Naomi Beck
RTRob A.E. M. Tollenaar
Rob A.E. M. Tollenaar
FSFranz M.N. H. Schramel
Franz M.N. H. Schramel
Accurate diagnosis and staging are crucial to ensure uniform allocation to the optimal treatment methods for non-small cell lung cancer (NSCLC) patients, but may differ among multidisciplinary tumor boards (MDTs). Discordance between clinical and pathologic TNM stage is particularly important for patients with locally advanced NSCLC (stage IIIA) because it may influence their chance of allocation to curative-intent treatment. We therefore aimed to study agreement on staging and treatment to gain insight into MDT decision-making. What is the level of agreement on clinical staging and treatment recommendations among MDTs in stage IIIA NSCLC patients? Eleven MDTs each evaluated the same 10 pathologic stage IIIA NSCLC patients in their weekly meeting (n = 110). Patients were selected purposively for their challenging nature. All MDTs received exactly the same clinical information and images per patient. We tested agreement in cT stage, cN stage, cM stage (TNM 8th edition), and treatment proposal among MDTs using Randolph’s free-marginal multirater kappa. Considerable variation among the MDTs was seen in T staging (κ, 0.55 [95% CI, 0.34-0.75]), N staging (κ, 0.59 [95% CI, 0.35-0.83]), overall TNM staging (κ, 0.53 [95% CI, 0.35-0.72]), and treatment recommendations (κ, 0.44 [95% CI, 0.32-0.56]). Most variation in T stage was seen in patients with suspicion of invasion of surrounding structures, which influenced such treatment recommendations as induction therapy and type. For N stage, distinction between N1 and N2 disease was an important source of discordance among MDTs. Variation occurred between 2 patients even regarding M stage. A wide range of additional diagnostics was proposed by the MDTs. This study demonstrated high variation in staging and treatment of patients with stage IIIA NSCLC among MDTs in different hospitals. Although some variation may be unavoidable in these challenging patients, we should strive for more uniformity.

1 August 2019 in Lung Cancer
Verified
Journal Article
Closed access
JBJelle E. Bousema
Jelle E. Bousema
MDMartijn van Dorp
Martijn van Dorp
FHFieke Hoeijmakers
Fieke Hoeijmakers
IHIlse A. Huijbregts
Ilse A. Huijbregts
NBNicole P. Barlo
Nicole P. Barlo
FBFrank J.C. van Den Broek
Frank J.C. van Den Broek

1 April 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
FHFieke Hoeijmakers
Fieke Hoeijmakers
DHDavid J. Heineman
David J. Heineman
NBNaomi Beck
Naomi Beck
JKJolien Klamer
Jolien Klamer
RTRob A.E.M. Tollenaar
Rob A.E.M. Tollenaar
WSWilhelmina H. Schreurs
Wilhelmina H. Schreurs

1 June 2021 in Chest
Verified
Journal Article
Open access
PDF file
DHDavid J. Heineman
David J. Heineman
FHFieke Hoeijmakers
Fieke Hoeijmakers
WSWilhelmina H. Schreurs
Wilhelmina H. Schreurs
We thank Dr Lampridis from General Military Hospital in Thessaloniki, Greece, for his response to our study on multidisciplinary team (MDT) meeting decision-making in locally advanced non-small cell lung cancer.1Hoeijmakers F. Heineman D.J. Daniels J.M. et al.Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer.Chest. 2020; 158: 2675-2687Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar We want to take this opportunity to answer to his comments.

1 February 2021 in Chest
Verified
Journal Article
Closed access
PDF file
FHF. Hoeijmakers
F. Hoeijmakers
DHDavid J. Heineman
David J. Heineman
WSW.H. Schreurs
W.H. Schreurs